Potential Antidepressants Displayed Combined α2-Adrenoceptor Antagonist and Monoamine Uptake Inhibitor Properties
- 3 February 2001
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 44 (5) , 787-805
Abstract
Classical antidepressants are thought to act by raising monoamine (serotonin and noradrenaline) levels in the brain. This action is generally accomplished either by inhibition of monoamine metabolism (MAO inhibitors) or by blockade of monoamine uptake (tricyclic antidepressants and selective serotonin or noradrenaline reuptake inhibitors). However, all such agents suffer from a time lag (3−6 weeks) before robust clinical efficacy can be demonstrated. This delay may reflect inhibitory actions of noradrenaline at presynaptic α2A-adrenergic auto- or heteroreceptors which gradually down-regulate upon prolonged exposure. Blockade of presynaptic α2A-adrenoceptors by an antagonist endowed with monoamine uptake inhibition properties could lead to new antidepressants with greater efficacy and a shorter time lag. In the literature, only two molecules have been described with such a pharmacological profile. Of these, napamezole (2) was chosen as a point of departure for the design of 4(5)-[(3,4-dihydro-2-naphthalenyl)methyl]-4,5-dihydroimidazole (4a), which displayed the desired profile: α2A-adrenoceptor antagonist properties and serotonin/noradrenaline uptake inhibition. From this original molecule, a series of derivatives was designed and synthesized, encompassing substituted as well as rigid analogues. Structure−activity relationships permitted the selection of 14c (4(5)-[(5-fluoroindan-2-yl)methyl]-4,5-dihydroimidazole) as a development candidate.Keywords
This publication has 20 references indexed in Scilit:
- Synthesis and pharmacological characterization of A-80426: A putative novel antidepressant combining α-2 antagonism with 5-HT uptake inhibitionBioorganic & Medicinal Chemistry Letters, 1995
- Design, synthesis, and structure-activity Relationships of a new series of .alpha.-adrenergic agonists: spiro[(1,3-diazacycylpent-1-ent)-5,2'-(1',2',3',4'-tetrahydronaphthalene)]Journal of Medicinal Chemistry, 1995
- A mild oxidizing reagent for alcohols and 1,2-diols: o-Iodoxybenzoic acid (IBX) in DMSOTetrahedron Letters, 1994
- Synthesis and pharmacological characterization of ABT-200: a putative novel antidepressant combining potent α-2 antagonism with moderate NE uptake inhibitionBioorganic & Medicinal Chemistry Letters, 1994
- Preparation of spirocyclic cyclopropyl ketones through condensation of epoxides with .beta.-keto phosphonatesThe Journal of Organic Chemistry, 1993
- Synthesis and structure-activity of 4(5)-(2,2-diphenylethyl)imidazoles as new α2-adrenoreceptor antagonistsEuropean Journal of Medicinal Chemistry, 1990
- Synthesis of .beta.-keto phosphonates from vinyl phosphates via a 1,3-phosphorus migrationThe Journal of Organic Chemistry, 1987
- The question of homoaromaticity in 1,6-dihydro-1,2,4,5-tetrazinesThe Journal of Organic Chemistry, 1986
- Synthesis of .beta.,.gamma.-unsaturated amino acids by the Strecker reactionThe Journal of Organic Chemistry, 1984
- Cyclopropan‐Verbindungen aus „Phosphoenolbrenztraubensäuretriäthylester”︁European Journal of Organic Chemistry, 1970